Evaluation of Two Doses of SR31747A (75 mg and 125 mg) in Non-Metastatic Androgen-Independent Prostate Cancer. Randomized, Double-Blind, Placebo Controlled Phase II Study.

Trial Profile

Evaluation of Two Doses of SR31747A (75 mg and 125 mg) in Non-Metastatic Androgen-Independent Prostate Cancer. Randomized, Double-Blind, Placebo Controlled Phase II Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2013

At a glance

  • Drugs SR 31747 (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms ODYSSEY
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Dec 2008 Actual initiation date (Oct 2003) added as reported by ClinicalTrials.gov.
    • 22 Dec 2008 Actual end date (Aug 2006) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top